Tirzepatide 30mg
Tirzepatide is a dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptors: a 39-amino-acid synthetic peptide based on the native GIP sequence with modifications conferring GLP-1 receptor co-agonism. A C20 fatty-diacid moiety linked through a glutamic acid and two mini-PEG spacers enhances albumin binding and in-vitro stability. Supplied strictly for in-vitro research and laboratory use only. Not for human or animal use.
Select Option
2+ save 5% · 5+ save 10% · 10+ save 20%
- Free Priority shipping on US orders over $100
- Ships same day on orders before 2 PM MST
- Discreet, unmarked packaging
- Third-party tested to a 99%+ purity standard
Mechanism of Action
Tirzepatide engages both the GIP receptor (GIPR) and the GLP-1 receptor (GLP-1R) with a bias toward GIPR (~5:1). In research models, GIPR activation in adipose tissue is studied for lipid storage and adipokine signaling, and central GIPR signaling for feeding-circuit pathways; the combined receptor engagement is used to study insulinotropic, glucagon, and energy-metabolism signaling relative to selective GLP-1R agonism.
Properties
Molecular Formula
C₂₂₅H₃₄₈N₄₈O₆₈
Molecular Weight
4813.45 Da
Half-Life
~5 days
Storage
Store lyophilized at -20°C. Reconstituted at 2-8°C, use within 30 days.
Shipping & Delivery
- Same-day dispatch on orders placed before 2 PM MST (Arizona — no daylight saving).
- US shipping from $5. Free Priority on orders $100+ (before discounts).
- Plain, unmarked packaging — no branding or product names on the outside.
- Ships to all 50 states, DC, Puerto Rico & the U.S. Virgin Islands; tracking emailed on every order.
Quality & Testing
- Independently tested by accredited third-party laboratories.
- Held to a 99%+ purity standard.
- USA-based; dispatched from Phoenix, Arizona.
- Supplied strictly for in-vitro laboratory research — not for human use.
Batch test records are published to each product as they are completed.
Research Applications
References & Citations
(5)Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2)
Frías JP, Davies MJ, Rosenstock J, et al.
LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept
Coskun T, Sloop KW, Loghin C, et al.
Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist
Willard FS, Douros JD, Gabe MB, et al.
Structural determinants of dual incretin receptor agonism by tirzepatide
Sun B, Willard FS, Feng D, et al.
GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice (animal study)
Samms RJ, Christe ME, Collins KA, et al.
Related Products
Research Use Only
This product is intended strictly for in-vitro research, educational, and laboratory use. Not for human consumption. The information provided is based on published research and does not constitute medical advice.